CN116059279A - Ginseng radix morinda officinalis herba cistanches tablet - Google Patents

Ginseng radix morinda officinalis herba cistanches tablet Download PDF

Info

Publication number
CN116059279A
CN116059279A CN202211546302.XA CN202211546302A CN116059279A CN 116059279 A CN116059279 A CN 116059279A CN 202211546302 A CN202211546302 A CN 202211546302A CN 116059279 A CN116059279 A CN 116059279A
Authority
CN
China
Prior art keywords
ginseng
cistanche
amount
preparation
morinda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211546302.XA
Other languages
Chinese (zh)
Inventor
张树春
张大文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202211546302.XA priority Critical patent/CN116059279A/en
Publication of CN116059279A publication Critical patent/CN116059279A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/487—Psoralea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A61K36/605—Morus (mulberry)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/64—Orobanchaceae (Broom-rape family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/746—Morinda
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention provides a ginseng morinda officinalis cistanche tablet which is prepared from the following components in parts by weight: ginseng 1 g-3 g (crude drug amount), morinda root (salt preparation): 3 g-15 g, cistanche deserticola (wine preparation): 5 g-15 g, fructus psoraleae (salt preparation): 6 g-10 g, mulberry: 10 g-15 g and proper amount of glucose. The nutrition formula composition of the invention has scientific and reasonable formula, combines kidney tonifying and kidney conditioning functions into a whole, can condition kidney physiology and regulate kidney functions, thereby achieving the effects of balancing yin and yang, nourishing yin and strengthening yang, beautifying and building body and improving immunity, has the efficacy of directly reaching affected parts, can quickly relieve pain, and has the advantages of quick response, no toxic or side effect and low cost.

Description

Ginseng radix morinda officinalis herba cistanches tablet
Technical Field
The invention belongs to the technical field of nutritional formulas, and particularly relates to ginseng morinda officinalis cistanche tablets.
Background
The current living environment and the dietary environment have more or less influence on the kidney, and the hypertension and diabetes groups have influence on the kidney due to the influence of medicines.
Disclosure of Invention
In order to overcome the defects of the prior art, the invention provides the ginseng morinda officinalis cistanche tablet.
In order to achieve the above purpose, the technical scheme of the invention is as follows:
the ginseng and morinda officinalis cistanche tablet is prepared from the following components in parts by weight: 3 g-15 g, cistanche deserticola (wine preparation): 5 g-15 g, fructus psoraleae (salt preparation): 6 g-10 g, mulberry: 10 g-15 g and proper amount of glucose.
The preferable scheme is as follows: the nutrition formula is prepared from the following components in parts by weight: ginseng 1 g-3 g (crude drug amount), morinda root (salt preparation): 5g, cistanche deserticola (wine): 7g, fructus psoraleae (salt): 7g, mulberry: 11g and a proper amount of glucose.
The preferable scheme is as follows: the nutrition formula is prepared from the following components in parts by weight: ginseng 1 g-3 g (crude drug amount), morinda root (salt preparation): 9g, cistanche deserticola (wine): 10g, fructus psoraleae (salt): 8g, mulberry: 12.5g and a proper amount of glucose.
The preferable scheme is as follows: the nutrition formula is prepared from the following components in parts by weight: ginseng 1 g-3 g (crude drug amount), morinda root (salt preparation): 15g, cistanche deserticola (wine): 15g, fructus psoraleae (salt): 10g, mulberry, 15g and a proper amount of glucose.
The invention also discloses a preparation method of the ginseng morinda officinalis cistanche tablet, which comprises the following steps:
s1: crushing a certain amount of morinda officinalis and fructus psoraleae, and sieving with a 400-mesh sieve;
s2: crushing a certain amount of cistanche deserticola at low temperature, and sieving with 400 mesh sieve; (note: cistanche deserticola contains hydrophilic colloid polysaccharide for several times, and the pulverizing time should not exceed 20 seconds;
s3: uniformly mixing the fine powder obtained after the S1 passes through a 400-mesh screen;
s4: uniformly mixing the S2 and the S3;
s5: taking a specified amount of mulberry, crushing, and adding into S4 for uniform mixing;
s6: crushing a prescribed amount of ginseng, and sieving with a 400-mesh sieve;
s7: adding glucose powder into S6, and mixing uniformly;
s8: uniformly mixing S2, S4, S5 and S7, sieving with a 16-mesh sieve, granulating, and drying in an oven at 40 ℃;
s9: spraying five parts per million of fruit essence on the dried S8, and sieving with a 40-mesh sieve to obtain granules;
s10: and (3) making the granules prepared in the steps S1 to S9 into tablets by a tablet press, and finishing the preparation.
The characteristics and the effects of the raw materials are as follows:
(1) Ginseng: rg2 contained in ginseng is a main component regulating kidney function: regulating central nervous system, enhancing immunity, and improving sleep; promoting secretion of corticotropin of secondary kidney (adrenal gland), and improving female climacteric syndrome and Parkinson syndrome. Meanwhile, the ginseng-based health care food also has very remarkable effects of tonifying kidney and strengthening yang, and can directly improve reproductive system functions of men after taking ginseng, especially improve sperm production capacity, effectively promote sperm motility, and eliminate symptoms such as soreness and weakness of waist and knees, night sweat and spontaneous perspiration caused by kidney deficiency.
(2) Radix Morindae officinalis: contains reducing sugar, glycoside, cardiac glycoside, flavone, steroid triterpene, amino acid, and organic acid; also contains 23 metal elements such as potassium, calcium, magnesium, etc. Kidney-tonifying yang-invigorating, tendons and bones-strengthening, wind-dispelling and dampness-eliminating, and treating kidney-deficiency impotence, spermatorrhea and premature ejaculation, cold pain of lower abdomen, infertility due to cold womb, etc., are kidney-meridian blood-dividing herbs, and stomach-qi is grown when reinforcing primordial yang, and the deficiency self-withdraws.
(3) Cistanche deserticola: cistanche salsa contains various amino acids required by human body, such as valine, can act on corpus luteum, mammary gland and ovary, and isoleucine acts on thyroid gland and gonad, and can help regulate endocrine. Comprises testosterone-like and estradiol-like substances; contains inorganic substances and microelements such as potassium, sodium, calcium, zinc, manganese, copper, etc. The substances such as eugenol glycoside and tulipifera glycoside can help promote sexual central nervous function and improve sexual desire. Replenishing essence and blood; moisten the intestinal tract. Deficiency of the kidney-yang; impotence due to deficiency of essence and blood; seminal emission; white turbidity; frequent urination and dribbling; lumbago and weakness of feet; tinnitus and blurred vision; a menstruation delay; infertility due to cold womb; constipation due to intestinal dryness. Sweet in taste; salty; sex warm and return to kidney; the large intestine channel. Cistanche deserticola has regulating effect on decrease and increase of liver and spleen nucleic acid content of animals with yang deficiency and yin deficiency; has effects of activating adrenal gland and releasing corticoid.
(4) Fructus psoraleae: contains coumarone, flavonoid, monoterpene phenol, volatile oil, soap, polysaccharide, lipoid, etc. And contains elements such as potassium, manganese, calcium, iron, copper, zinc, arsenic, antimony, rubidium, strontium, selenium and the like. Can be used for treating sexual impotence due to kidney deficiency, soreness and cold pain of waist and knee, nocturnal emission due to kidney deficiency, enuresis, frequent urination, etc., and can be used for treating sexual impotence, nocturnal emission, cold pain of waist and knee, etc. caused by kidney yang deficiency.
(5) Mulberry: the mulberry is good in big, dark purple, oily and thick. Mulberry contains rich glucose, fructose, citric acid, tannic acid, malic acid, calcium and the like. Mulberry has effects of nourishing yin, invigorating kidney, strengthening tendons and bones, and can be used for relieving discomfort such as soreness of waist and knees, spermatorrhea, sexual impotence, premature ejaculation, spermatorrhea, night sweat, etc. caused by kidney deficiency.
The beneficial effects are that: the formula of the combined medicine is scientific and reasonable, and the compatibility of medicines is combined with cooling and heating, so that the offset of the medicines is neutralized, and the effects of tonifying kidney and strengthening yang are improved. The product combines kidney tonifying and kidney regulating functions, and can regulate kidney physiology and kidney function, thereby achieving the effects of balancing yin and yang, nourishing yin and strengthening yang, beautifying and building body and improving immunity.
Detailed Description
The invention is described below with reference to specific examples. It will be appreciated by those skilled in the art that these examples are for illustration of the invention only and are not intended to limit the scope of the invention in any way.
Example 1
The nutrition formula of the invention is prepared from the following components in parts by weight: ginseng 1 g-3 g (crude drug amount), morinda root (salt preparation): 5g, cistanche deserticola (wine): 7g, fructus psoraleae (salt): 7g, mulberry: 11g and a proper amount of glucose. .
Example 2
The nutrition formula of the invention is prepared from the following components in parts by weight: ginseng 1 g-3 g (crude drug amount), morinda root (salt preparation): 9g, cistanche deserticola (wine): 10g, fructus psoraleae (salt): 8g, mulberry: 12.5g and a proper amount of glucose.
Example 3
The nutrition formula of the invention is prepared from the following components in parts by weight: ginseng 1 g-3 g (crude drug amount), morinda root (salt preparation): 15g, cistanche deserticola (wine): 15g, fructus psoraleae (salt): 10g, mulberry, 15g and a proper amount of glucose.
The invention also discloses a preparation method of the ginseng morinda officinalis cistanche tablet, which comprises the following steps:
s1: crushing a certain amount of morinda officinalis and fructus psoraleae, and sieving with a 400-mesh sieve;
s2: crushing a certain amount of cistanche deserticola at low temperature, and sieving with 400 mesh sieve; (note: cistanche deserticola contains hydrophilic colloid polysaccharide for several times, and the pulverizing time should not exceed 20 seconds;
s3: uniformly mixing the fine powder obtained after the S1 passes through a 400-mesh screen;
s4: uniformly mixing the S2 and the S3;
s5: taking a specified amount of mulberry, crushing, and adding into S4 for uniform mixing;
s6: crushing a prescribed amount of ginseng, and sieving with a 400-mesh sieve;
s7: adding glucose powder into S6, and mixing uniformly;
s8: uniformly mixing S2, S4, S5 and S7, sieving with a 16-mesh sieve, granulating, and drying in an oven at 40 ℃;
s9: spraying five parts per million of fruit essence on the dried S8, and sieving with a 40-mesh sieve to obtain granules;
s10: and (3) making the granules prepared in the steps S1 to S9 into tablets by a tablet press, and finishing the preparation.
Typical cases:
case 1: patients Zhao Moujun, men, have been married, 48 years old, 11 years old, 5 and 6 years old, have taken other drugs for treating impotence and premature ejaculation, which is not ideal. The specific expression is that after the product is introduced by friends to be taken for one week, symptoms are greatly improved, and the product can be taken for 3 months, so that more normal sexual life can be carried out.
Case 2: the patient Liu Mou, men, 26 years old, is frightened by the accident and has improved living environment and normal sexual life after introducing and taking the product by friends and psychological coaching.
Case 3: patients Li Mou yuan, men, 56 years old, take antihypertensive drugs for hypertension throughout the year, and impotence is caused by the drugs. After the product is introduced by friends to take for 3 months, the sexual life gradually returns to normal.
The above description of the specific embodiments of the present invention is given by way of example only, and the present invention is not equivalent to the above-described specific embodiments. Any equivalent modifications and substitutions for the present invention will occur to those skilled in the art, and are also within the scope of the present invention. Accordingly, equivalent changes and modifications to the disclosed embodiments will be apparent from the following detailed description, given herein, without departing from the spirit and scope of the present invention.

Claims (5)

1. The ginseng morinda officinalis cistanche tablet is characterized by being prepared from the following components in parts by weight: ginseng 1 g-3 g (crude drug amount), morinda root (salt preparation): 3 g-15 g, cistanche deserticola (wine preparation): 5 g-15 g, fructus psoraleae (salt preparation): 6 g-10 g, mulberry: 10 g-15 g and proper amount of glucose.
2. The ginseng morinda officinalis cistanche tablet according to claim 1, wherein the nutritional formula is prepared from the following components in parts by weight: ginseng 1 g-3 g (crude drug amount), morinda root (salt preparation): 5g, cistanche deserticola (wine): 7g, fructus psoraleae (salt): 7g, mulberry: 11g and a proper amount of glucose.
3. The ginseng morinda officinalis cistanche tablet according to claim 1, wherein the nutritional formula is prepared from the following components in parts by weight: ginseng 1 g-3 g (crude drug amount), morinda root (salt preparation): 9g, cistanche deserticola (wine): 10g, fructus psoraleae (salt): 8g, mulberry: 12.5g and a proper amount of glucose.
4. The ginseng morinda officinalis cistanche tablet according to claim 1, wherein the nutritional formula is prepared from the following components in parts by weight: ginseng 1 g-3 g (crude drug amount), morinda root (salt preparation): 15g, cistanche deserticola (wine): 15g, fructus psoraleae (salt): 10g, mulberry, 15g and a proper amount of glucose.
5. The method for preparing the ginseng morinda officinalis cistanche tablet according to any one of claims 1 to 4, which is characterized by comprising at least the following preparation steps:
s1: crushing a certain amount of morinda officinalis and fructus psoraleae, and sieving with a 400-mesh sieve;
s2: crushing a certain amount of cistanche deserticola at low temperature, and sieving with 400 mesh sieve; (note: cistanche deserticola contains hydrophilic colloid polysaccharide for several times, and the pulverizing time should not exceed 20 seconds;
s3: uniformly mixing the fine powder obtained after the S1 passes through a 400-mesh screen;
s4: uniformly mixing the S2 and the S3;
s5: taking a specified amount of mulberry, crushing, and adding into S4 for uniform mixing;
s6: crushing a prescribed amount of ginseng, and sieving with a 400-mesh sieve;
s7: adding glucose powder into S6, and mixing uniformly;
s8: uniformly mixing S2, S4, S5 and S7, sieving with a 16-mesh sieve, granulating, and drying in an oven at 40 ℃;
s9: spraying five parts per million of fruit essence on the dried S8, and sieving with a 40-mesh sieve to obtain granules;
s10: and (3) making the granules prepared in the steps S1 to S9 into tablets by a tablet press, and finishing the preparation.
CN202211546302.XA 2022-12-05 2022-12-05 Ginseng radix morinda officinalis herba cistanches tablet Pending CN116059279A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211546302.XA CN116059279A (en) 2022-12-05 2022-12-05 Ginseng radix morinda officinalis herba cistanches tablet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211546302.XA CN116059279A (en) 2022-12-05 2022-12-05 Ginseng radix morinda officinalis herba cistanches tablet

Publications (1)

Publication Number Publication Date
CN116059279A true CN116059279A (en) 2023-05-05

Family

ID=86181132

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211546302.XA Pending CN116059279A (en) 2022-12-05 2022-12-05 Ginseng radix morinda officinalis herba cistanches tablet

Country Status (1)

Country Link
CN (1) CN116059279A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102552645A (en) * 2011-11-21 2012-07-11 宁波海逸生物科技有限公司 Formula of kidney-tonifying and yang-strengthening health-care medicament
CN103725532A (en) * 2012-10-13 2014-04-16 钱宝明 Epimedium health wine for impotence
CN114099457A (en) * 2021-12-14 2022-03-01 张红 Capsule for replenishing essence and blood and its preparation method

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102552645A (en) * 2011-11-21 2012-07-11 宁波海逸生物科技有限公司 Formula of kidney-tonifying and yang-strengthening health-care medicament
CN103725532A (en) * 2012-10-13 2014-04-16 钱宝明 Epimedium health wine for impotence
CN114099457A (en) * 2021-12-14 2022-03-01 张红 Capsule for replenishing essence and blood and its preparation method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
岳秀奎 等: "回春至宝丹治疗阳萎的临床观察", 黑龙江中医药, no. 03, pages 37 *

Similar Documents

Publication Publication Date Title
CN102178912B (en) Chinese medicine preparation for relieving gastral cavity crymodynia symptoms of people with yang deficiency as well as preparation method and application thereof
CN110584132A (en) Special medical nutritional formula food for kidney diseases and preparation method thereof
CN113616709A (en) A Chinese medicinal composition for treating male infertility, and its preparation method
CN104547822A (en) Traditional Chinese medicinal composition for treating child enuresis and preparation method of preparations thereof
CN105687490A (en) Medicine for treating impotence, premature ejaculation and sexual dysfunction and preparation method thereof
CN1319403A (en) Medicine for treating allergic purpura
CN111387498A (en) Pilose antler-oyster soft capsule for quickly improving male sexual function and preparation method thereof
CN116059279A (en) Ginseng radix morinda officinalis herba cistanches tablet
CN112546183A (en) Health-care plaster containing Chinese mugwort, navel and red bean
CN108837131A (en) A kind of Chinese herbal compounds are promoted the sexual maturity scattered and preparation method thereof
CN108272958A (en) It is a kind of to have effects that improve the composition of male sexual
CN107998229A (en) The Chinese medicine and its processing method that a kind of tonifying kidney and strengthening yang, replenishing essence are reinforced the kidney
CN113663023A (en) A Ganoderma composition for treating hypertension and its preparation method
CN102178870B (en) Chinese medicinal preparation for promoting qi circulation, promoting blood circulation, softening hard mass and eliminating stagnation for people with qi-depression and phlegm-damp physique, preparation method thereof and application thereof
CN112515030A (en) Candy for improving male function and preparation method thereof
CN104988020A (en) Conditioning wine, and preparation method and drinking method thereof
CN104988017A (en) Health-care fruit wine and preparation method thereof
CN100394922C (en) Toxicity-expelling fibrous nutrient and its prepn. method
CN104988019A (en) Fruit wine and preparation method thereof
CN109223999A (en) A kind of Chinese medicine improving digestive system function and production method and edible way
CN108671199B (en) Chinese herbal medicine composition for regulating spleen and stomach diseases and preparation method thereof
CN106421099A (en) Medicine capable of improving male sexual function and preparation method of medicine
CN108210658A (en) Tortoise deer preparation
CN101317918A (en) Kidney tonifying plaster medicine
CN111150781A (en) Kidney-warming yang-strengthening and body-strengthening pills and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination